{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:02:15Z","timestamp":1790240535875,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in neuropathic pain management and combination with opioids. A relatively favorable adverse effects profile, including no depressive effect on the respiratory system, may make cannabis complement a rather narrow armamentarium that is in the disposition of a palliative care professional.<\/jats:p>","DOI":"10.3390\/cancers11020129","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T03:52:32Z","timestamp":1548301952000},"page":"129","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-5695","authenticated-orcid":false,"given":"Tomasz","family":"Dzier\u017canowski","sequence":"first","affiliation":[{"name":"Laboratory of Palliative Medicine, Department of Social Medicine and Public Health, Medical University of Warsaw, ul. Oczki 3, 02-007 Warszawa, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for Medical Use: A Systematic Review and Meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MEG.0000000000000779","article-title":"Role of cannabis in digestive disorders","volume":"29","author":"Goyal","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0306-4522(97)00436-3","article-title":"Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system","volume":"83","author":"Tsou","year":"1998","journal-title":"Neuroscience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Marsicano","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"DePetrillo","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/dmrr.764","article-title":"CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance; metabolism; and cardiovascular health","volume":"23","author":"Cota","year":"2007","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbrc.2007.09.099","article-title":"The expression of receptors for endocannabinoids in human and rodent skeletal muscle","volume":"364","author":"Cavuoto","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","article-title":"Cannabinoid receptors and pain","volume":"63","author":"Pertwee","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1073\/pnas.0504187103","article-title":"Peripheral cannabinoid receptor; CB2; regulates bone mass","volume":"103","author":"Ofek","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1158\/0008-5472.CAN-07-2785","article-title":"Cannabinoids for cancer treatment: Progress and promise","volume":"68","author":"Sarfaraz","year":"2008","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.yebeh.2016.11.016","article-title":"Pharmacology of cannabinoids in the treatment of epilepsy","volume":"70","author":"Gaston","year":"2017","journal-title":"Epilepsy Behav."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8400","DOI":"10.1073\/pnas.122196999","article-title":"An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors","volume":"99","author":"Huang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pnpbp.2012.02.009","article-title":"Cannabinoid receptors: Nomenclature and pharmacological principles","volume":"38","author":"Marcu","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/med.20135","article-title":"Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids","volume":"29","author":"Hanus","year":"2009","journal-title":"Med. Res. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparation in saga; science; and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3732\/ajb.91.6.966","article-title":"A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae)","volume":"91","author":"Hillig","year":"2004","journal-title":"Am. J. Bot."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/156802608783498023","article-title":"CB receptor ligands from plants","volume":"8","author":"Woelkart","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_23","unstructured":"(2018, December 10). An Overview of Cannabis Potency in Europe; European Monitoring Centre for Drugs and Drug Addiction. Available online: http:\/\/www.emcdda.europa.eu\/publications\/insights\/cannabis-potency."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1300\/J175v01n03_10","article-title":"Cannabis \u201cvaporization\u201d: A promising strategy for smoke harm reduction","volume":"1","author":"Gieringer","year":"2001","journal-title":"J. Cannabis Ther."},{"key":"ref_25","unstructured":"(2018, December 10). Information for Health Care Professionals. Cannabis (Marihuana; Marijuana) and the Cannabinoids. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medical-use-marijuana\/information-medical-practitioners\/information-health-care-professionals-cannabis-marihuana-marijuana-cannabinoids.html#chp10."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.intimp.2005.10.002","article-title":"Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways","volume":"6","author":"Verhoeckx","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jep.2007.05.019","article-title":"Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea","volume":"113","author":"Hazekamp","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1360-0443.1996.911115852.x","article-title":"Cannabis: Pharmacology and toxicology in animals and humans","volume":"91","author":"Adams","year":"1996","journal-title":"Addiction"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"40","author":"MacCallum","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/1039856216663733","article-title":"Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review","volume":"24","author":"Courts","year":"2016","journal-title":"Australas. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.21037\/jtd.2017.06.104","article-title":"Role of cannabis in cardiovascular disorders","volume":"9","author":"Goyal","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40119-017-0102-x","article-title":"Cardiovascular Complications of Marijuana and Related Substances: A Review","volume":"7","author":"Singh","year":"2018","journal-title":"Cardiol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2011.1961","article-title":"Association between marijuana exposure and pulmonary function over 20 years","volume":"307","author":"Pletcher","year":"2012","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ijc.29036","article-title":"Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium","volume":"136","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.addbeh.2013.01.013","article-title":"Health outcomes associated with long-term regular cannabis and tobacco smoking","volume":"38","author":"Rooke","year":"2013","journal-title":"Addict. Behav."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","article-title":"Epidemiological characteristics; safety and efficacy of medical cannabis in the elderly","volume":"49","author":"Abuhasira","year":"2008","journal-title":"Eur. J. Intern. Med."},{"key":"ref_40","first-page":"33","article-title":"Cannabidiol as an intervention for addictive behaviors: A systematic review of the evidence","volume":"9","author":"Cata","year":"2015","journal-title":"Subst. Abuse"},{"key":"ref_41","first-page":"e78","article-title":"Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Physician"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.drugalcdep.2014.07.027","article-title":"Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: Cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum","volume":"143","author":"Bonnet","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1521-0391.2014.12088.x","article-title":"Cannabis withdrawal in chronic; frequent cannabis smokers during sustained abstinence within a closed residential environment","volume":"23","author":"Lee","year":"2014","journal-title":"Am. J. Addict."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.drugalcdep.2010.11.004","article-title":"Probability and predictors of transition from first use to dependence on nicotine; alcohol; cannabis; and cocaine: Results of the national epidemiologic survey on alcohol and related conditions (NESARC)","volume":"115","author":"Hasin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/dar.12183","article-title":"Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Well-Being","volume":"33","author":"Butterworth","year":"2014","journal-title":"Drug Alcohol Rev."},{"key":"ref_47","unstructured":"(2018, December 10). Sativex\u00ae Product Monograph. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00016162.PDF."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ejp.1147","article-title":"Availability and approval of cannabis-based medicines for chronic pain management and palliative\/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation","volume":"22","author":"Wells","year":"2018","journal-title":"Eur. J. Pain"},{"key":"ref_49","unstructured":"(2018, December 10). Marinol\u00ae Product Monograph. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00013378.PDF."},{"key":"ref_50","unstructured":"(2018, December 10). Cesamet\u00ae Product Monograph. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00007760.PDF."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lanz, C., Mattsson, J., Soydaner, U., and Brenneisen, R. (2016). Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147286"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J175v04n01_02","article-title":"Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds","volume":"4","author":"Gieringer","year":"2004","journal-title":"J. Cannabis Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/jps.20574","article-title":"Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol","volume":"95","author":"Hazekamp","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000112901","article-title":"The perceived effects of cannabis smoking in patients with multiple sclerosis","volume":"38","author":"Consroe","year":"1997","journal-title":"Eur. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1046\/j.1365-2044.2001.02269.x","article-title":"Pharmacological actions and therapeutic uses of cannabis and cannabinoids","volume":"56","author":"Kumar","year":"2001","journal-title":"Anaesthesia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ctim.2017.08.010","article-title":"Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Jardini","year":"2017","journal-title":"Complement. Ther. Med."},{"key":"ref_57","first-page":"279","article-title":"Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy","volume":"41","author":"Amato","year":"2017","journal-title":"Epidemiol. Prev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/0269215517745348","article-title":"A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: A systematic review and network meta-analysis","volume":"32","author":"Fu","year":"2018","journal-title":"Clin. Rehabil."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2018.01.003","article-title":"The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report","volume":"40","author":"Abrams","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11910-018-0814-x","article-title":"The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: A Systematic Review of Reviews","volume":"18","author":"Nielsen","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/2327-6924.12422","article-title":"State of the evidence: Cannabinoids and cancer pain-A systematic review","volume":"29","author":"Tateo","year":"2017","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.lfs.2003.09.038","article-title":"Synergistic interactions between cannabinoid and opioid analgesics","volume":"74","author":"Cichewicz","year":"2004","journal-title":"Life Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J. Pain Symptom Manag."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","article-title":"Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial","volume":"13","author":"Portenoy","year":"2012","journal-title":"J. Pain"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: Systematic review; meta-analysis and updated NeuPSIG recommendations","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/jcsm.12273","article-title":"Systematic review and meta-analysis of cannabinoids in palliative medicine","volume":"9","author":"Weier","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: A systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/can.2016.0006","article-title":"Cannabinoid regulation of acute and anticipatory nausea","volume":"1","author":"Rock","year":"2016","journal-title":"Cannabis Cannabinoid Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.323.7303.16","article-title":"Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review","volume":"323","author":"Carroll","year":"2001","journal-title":"BMJ"},{"key":"ref_70","first-page":"2406","article-title":"Nausea and vomiting in people with cancer and other chronic diseases","volume":"2009","author":"Keeley","year":"2009","journal-title":"BMJ Clin. Evid."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00482-015-0092-3","article-title":"Efficacy; tolerability; and safety of cannabinoids for chemotherapy-induced nausea and vomiting\u2014A systematic review of systematic reviews","volume":"30","author":"Tafelski","year":"2016","journal-title":"Schmerz"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ptr.5975","article-title":"Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews","volume":"32","author":"Schussel","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_73","unstructured":"(2018, December 10). Nabilone for Non-Chemotherapy Associated Nausea and Weight Loss due to Medical Conditions, A Review of the Clinical Effectiveness and Guidelines, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK253668\/."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the Treatment of Epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the Treatment of Epilepsy, Hard Evidence at Last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J. Epilepsy Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","article-title":"Cannabinoids in treatment-resistant epilepsy, A review","volume":"70","author":"Gloss","year":"2017","journal-title":"Epilepsy Behav."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc1512758","article-title":"Cannabinoids in the Treatment of Epilepsy","volume":"374","author":"Killestein","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","article-title":"Cannabis, Cannabinoids, and Sleep, a Review of the Literature","volume":"19","author":"Babson","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"J. Pain Symptom Manag."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/106002809302700701","article-title":"Effect of dronabinol on nutritional status in HIV infection","volume":"27","author":"Struwe","year":"1993","journal-title":"Ann. Pharmacother."},{"key":"ref_82","first-page":"CD005175","article-title":"The medical use of cannabis for reducing morbidity and mortality in patients with HIV\/AIDS","volume":"4","author":"Lutge","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/aid.1997.13.305","article-title":"Division of AIDS Treatment Research Initiative. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome, the DATRI 004 Study Group","volume":"13","author":"Timpone","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdq727","article-title":"Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial","volume":"22","author":"Brisbois","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/bjo.2003.032250","article-title":"Cannabinoids and glaucoma","volume":"88","author":"Tomida","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/ICU.0000000000000242","article-title":"Cannabinoids for treatment of glaucoma","volume":"27","author":"Novack","year":"2016","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","article-title":"Effect of sublingual application of cannabinoids on intraocular pressure, a pilot study","volume":"15","author":"Tomida","year":"2006","journal-title":"J. Glaucoma"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC), a randomized crossover trial","volume":"35","author":"Schneider","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome, a 6-week randomized trial","volume":"64","author":"Schneider","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.canlet.2009.04.005","article-title":"Cannabinoids in the treatment of cancer","volume":"285","author":"Alexander","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.3747\/co.23.3080","article-title":"Anticancer mechanisms of cannabinoids","volume":"23","author":"Velasco","year":"2016","journal-title":"Curr. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bjc.6603236","article-title":"A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme","volume":"95","author":"Duarte","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999\u20132010","volume":"174","author":"Bachhuber","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"Finn","year":"2018","journal-title":"Eur. J. Pain"},{"key":"ref_95","first-page":"111","article-title":"Simplified guideline for prescribing medical cannabinoids in primary care","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/2\/129\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:28:03Z","timestamp":1760185683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/2\/129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":95,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["cancers11020129"],"URL":"https:\/\/doi.org\/10.3390\/cancers11020129","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]}}}